Table 1.

Associations of Genetically Predicted vWF, ETP, d-Dimer, FVIII, tPA, and PAI-1 With CAD/MI and MI Using Mendelian Randomization With Different Methodological Approaches

Exposure*OutcomeMethodOutcome Study With the Same ImputationOutcome Study With Different Imputation
Outcome StudyNo. of SNPsOR95% CIIntercept P ValueOutcome studyNo. of SNPsOR95% CIIntercept P Value
vWF (SD)CAD/MIIVWMetabochip161.051.02–1.081000 G161.051.03–1.08
WM161.061.03–1.09161.071.04–1.10
MR Egger161.061.02–1.110.38161.071.03–1.120.32
CAD/MI without rs687621 (ABO)IVWMetabochip151.010.95–1.08151.020.98–1.06
WM151.050.96–1.14151.010.96–1.06
MR Egger150.990.83–1.180.82151.0030.91–1.110.60
MIIVWMetabochipNANANA1000 G161.091.06–1.12
WMNANANA161.131.09–1.17
MR EggerNANANANA161.131.08–1.190.05
MI without rs687621 (ABO)IVWMetabochipNANANA1000 G151.030.98–1.07
WMNANANA151.020.96–1.08
MR EggerNANANANA150.990.89–1.110.48
ETP (SD)CAD/MIWGLM1000 G151.051.03–1.07MetabochipNANANA
WM141.041.01–1.07NANANA
MR Egger151.020.98–1.060.51NANANANA
MIWGLM1000 G151.081.06–1.11MetabochipNANANA
WM141.071.04–1.10NANANA
MR Egger151.040.99–1.090.48NANANANA
d-dimer (SD)CAD/MIIVWMetabochip31.020.87–1.191000 G30.990.92–1.08
WM31.000.83–1.2130.990.90–1.08
MIIVWMetabochipNANANA1000 G30.970.89–1.07
WMNANANA30.940.85–1.05
FVIII (SD)CAD/MIIVWMetabochip61.061.03–1.091000 G61.081.05–1.12
WM61.061.03–1.0961.081.04–1.12
MR Egger61.051.004–1.110.7261.071.02–1.120.47
CAD/MI without potentially pleiotropic SNPsIVWMetabochip41.070.90–1.271000 G41.141.02–1.28
WM41.060.84–1.3441.130.96–1.32
MR Egger40.780.38–1.600.3840.930.58–1.470.37
MIIVWMetabochipNANANA1000 G61.141.10–1.19
WMNANANA61.141.10–1.19
MR EggerNANANANA61.141.08–1.190.76
MI without potentially pleiotropic SNPsIVWMetabochipNANANA1000 G41.141.01–1.30
WMNANANA41.140.96–1.36
MR EggerNANANANA40.960.57–1.620.50
tPA, ng/mLCAD/MIIVWMetabochip30.950.54–1.671000 G31.120.75–1.67
WM31.220.60–2.4831.140.69–1.87
MIIVWMetabochipNANANA1000 G31.410.90–2.22
WMNANANA31.680.98–2.90
PAI-1, ng/mLCAD/MIWGLMMetabochip51.180.95–1.481000 G51.281.10–1.48
WM40.940.67–1.3141.210.97–1.50
MR Egger50.360.13–1.050.0350.500.24–1.020.009
MIWGLMMetabochipNANANA1000 G51.120.94–1.32
WMNANANA41.130.89–1.44
MR EggerNANANANA50.330.14–0.780.005*
  • 1000 G indicates 1000 Genome; CAD/MI, coronary artery disease/myocardial infarction; CI, confidence interval; ETP, endogenous thrombin potential; FVIII, factor VIII; IVW, inverse variance weighting; OR, odds ratio; NA, not available; PAI, plasminogen activator inhibitor; SNP, single-nucleotide polymorphism; tPA, tissue-type plasminogen activator; vWF, von Willebrand factor; WGLM, weighted generalized linear regression model; and WM, weighted median method.

  • * ETP, d-dimer, tPA, and PAI-1 were log transformed in the genome-wide association studies providing genetic associations. Weighted median method was conducted in uncorrelated SNPs, so correlated SNPs (rs3136516 for ETP and rs314376 for PAI-1) were deleted.

  • Only 1 SNP (rs17787912) for ETP was available in CARDIoGRAMplusC4D Metabochip or CARDIOGRAM, so we only estimated the association in CARDIoGRAMplusC4D 1000 Genomes.